Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 20/20 | 0.59 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30990969 | 1.00 | MAPK1 (0.59) | MAPK1MAPK3 | |
| SCHEMBL18765621 | 0.91 | MAPK1 (0.70) | MAPK1MAPK3 | |
| SCHEMBL30225722 | 0.89 | MAPK1 (0.59) | MAPK1MAPK3 | |
| SCHEMBL18793727 | 0.89 | MAPK1 (0.59) | MAPK1MAPK3 | |
| SCHEMBL18765536 | 0.86 | MAPK1 (0.58) | MAPK1 | |
| SCHEMBL18765903 | 0.82 | MAPK1 (0.67) | MAPK1MAPK3 | |
| SCHEMBL18765699 | 0.82 | MAPK1 (0.72) | MAPK1MAPK3 | |
| SCHEMBL29676756 | 0.82 | MAPK1 (0.72) | MAPK1MAPK3 | |
| SCHEMBL30990930 | 0.80 | MAPK1 (0.76) | MAPK1MAPK3 | |
| SCHEMBL18765828 | 0.80 | MAPK1 (0.76) | MAPK1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114948963-B | Benzolactam compounds as protein kinase inhibitors | 大冢制药株式会社 | 2025-05-27 | — | — | CN | disclosed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| CN-108617166-B | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-05-17 | — | — | CN | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| EP-3365334-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068412-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017068412-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | MAPK1 1/4885MAPK3 17/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | MAPK1 1/4885MAPK3 17/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | MAPK1 1/4885MAPK3 19/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | MAPK1 1/4885MAPK3 17/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | MAPK1 1/4885MAPK3 16/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | MAPK1 1/4885MAPK3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.